135660-93-4

Usage

Uses

Used in Organic Synthesis:
α-bromo-o-fluorobenzoic acid methyl ester is used as a building block for the synthesis of various pharmaceutical compounds and advanced materials. Its unique molecular structure and reactivity make it a valuable intermediate in the creation of new drugs and materials.
Used in Pharmaceutical Research:
In the pharmaceutical industry, α-bromo-o-fluorobenzoic acid methyl ester is used as a key intermediate in the synthesis of active pharmaceutical ingredients. Its properties contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemicals:
α-bromo-o-fluorobenzoic acid methyl ester is also employed in the synthesis of agrochemicals, where it serves as a crucial intermediate for the development of new compounds with potential applications in agriculture. This includes the creation of pesticides and other agrochemical products that can improve crop yields and protect against pests.

Upstream product

• 192884-55-2 methyl 2-(2-fluorophenyl)-2-hydroxyacetate 
• 451-82-1 (2-fluorophenyl)acetic acid 
• 57486-67-6 methyl o-fluorophenylacetate 
• 446-52-6 2-Fluorobenzaldehyde 
• 389-31-1 2-fluoromandelic acid 

Downstream Products

• 181040-24-4 methyl (RS)-[2-cyano-5-(thien-3-ylmethoxy)phenoxy]-(2-fluorophenyl)acetate 
• 1218019-39-6 (2-fluoro-phenyl)-phenylamino-acetic acid methyl ester 
• 444892-79-9 4-[(2-fluoro-phenyl)-methoxycarbonyl-methyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, to methods of preparing such derivatives, to compositions comprising them and therapeutic use thereof.

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives

The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ETA receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ETA antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC50 59 nM, rat aortic ET(A)). Optimization of 13a led to the identification of 27b, which exhibited an IC50 of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 μmol/kg) and was duly proposed and accepted as a development candidate.

Antimuscarinic bronchodilators

Compounds having the formula: STR1 wherein X is either (a) a phenyl group optionally substituted by 1 or 2 substituents each independently selected from halo, CF3, C1 -C4 alkyl, C1 -C4 alkoxy and hydr

Antimuscarinic bronchodilators

Compounds having the formula: wherein X is either (a) a phenyl group optionally substituted by 1 or 2 substituents each independently selected from halo, CR3, C1-C4 alkyl, C1-C4 alkoxy and hydroxy, or